Pedro de Noronha Pissarra, PhD

Chief Executive Officer, Chrysea Labs

Pedro is an established, highly networked and seasoned life-sciences entrepreneur, having a 25-year track-record in the biotechnology and healthcare industry.

A graduate and post-graduate of Kings College London he carried out research at MIT, the Technical University of Denmark (DTU), Técnico Lisbon (IST) and obtained a Masters in Management from UT Texas, Austin.

He founded in 1996 and sold in 2018 the Biotecnol SA Group of companies, Rodon Biologics (sold to the Iberfar Group) and Biotecnol Limited (sold to Chiome, Inc). Pedro was a Board Member of Vida Rhein SA, part of the Rhein Biotech group, developing hepatitis vaccines (sold to Dynavax, Inc) and Board Member of 4Tune Engineering, a world leading company in Industry 4.0 data-driven and risk-analysis driven bioprocessing.

Pedro has collected over the years numerous awards for his pioneering achievements in bioentrepreneurship.